Third Harmonic Bio | Investor Presentation Deck

Third Harmonic Bio | Investor Presentation Deck | 20 slides

Third Harmonic Bio · 2022-10

arc beats above · slides in the middle · loops below · scroll → 2 LOOPS

Deck intelligence map

coverage by narrative range · generated from this deck JSON

Narrative range 14 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 17 hits

— 0/3 slides

33.3% 1/3 slides 33.3% 1/3 slides 100% 3/3 slides 100% 3/3 slides Product 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits

— 0/1 slides

100% 1/1 slides · 2 hits

— 0/1 slides

Solution 8 slides 100% 8/8 slides 100% 8/8 slides · 36 hits

— 0/8 slides

12.5% 1/8 slides 100% 8/8 slides · 9 hits

— 0/8 slides

Why Now 1 slides 100% 1/1 slides 100% 1/1 slides · 9 hits

— 0/1 slides

100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides The Ask 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits

— 0/1 slides

100% 1/1 slides 100% 1/1 slides

— 0/1 slides

Slide inventory

every slide · same image gating as the playbook

front_matter

Open slide detail

other

Open slide detail

The slide uses a four-column layout to summarize the market, target, product, and pipeline potential.summarize

Open slide detail

The slide uses a central hub-and-spoke diagram to show the mast cell as the central point of failure/intervention.frame_problem

Open slide detailBeat · ProblemLoop · Cost Of Inaction

Includes a patient quote and clinical imagery to emphasize the severity of the condition.frame_problem

Open slide detailBeat · ProblemLoop · Cost Of Inaction

frame_problem

Open slide detailBeat · ProblemLoop · Cost Of Inaction

The slide presents interim Phase 1b data from a study by Maurer et al. (EAACI, 2022).show_traction

Open slide detailBeat · Solution

The slide uses a combination of a bulleted list for qualitative benefits and a table for quantitative selectivity data.present_solution

Open slide detailBeat · Product

The slide uses a staircase diagram to represent dose escalation and a crossover design for the food effect study.present_framework

Open slide detailBeat · Solution

The chart displays multiple dose regimens (200mg QD, 200mg BID, 500mg QD FED, 400mg BID) with error bars representing standard deviation.analyze_data

Open slide detailBeat · Solution

MAD = Multiple Ascending Dose; SAE = Serious Adverse Event; AE = Adverse Event; ANC = Absolute Neutrophil Count; PBO = Placebo.analyze_data

Open slide detailBeat · Solution

The chart tracks neutrophil levels from Day 1 to Day 70/EOS, with an 'End of treatment' marker at Day 14.analyze_data

Open slide detailBeat · Solution

Includes a disclaimer about the reliability of cross-study comparisons.compare_peers

Open slide detailBeat · Solution

Includes two line charts with error bars representing mean +/- SD. LLOQ marked on the absolute chart.analyze_data

Open slide detailBeat · Solution

The schematic illustrates a dose-escalation study with three cohorts of 10 patients each, followed by a 4-week follow-up period.plan_implementation

Open slide detail

Data presented as Mean ± SD. Logarithmic scale on Y-axis.show_traction

Open slide detail

The slide combines mechanistic biological data (Maun et al.) with clinical trial results (Cahill et al., NEJM) to justify targeting mast cells in severe asthma.argue_timing

Open slide detailBeat · Why NowLoop · Why Now

The slide outlines a randomized, placebo-controlled trial structure with specific weeks and days for allergen challenges and measurements.plan_implementation

Open slide detail

The slide uses a timeline-based visualization to show clinical progress and pairs it with financial status.plan_implementation

Open slide detailBeat · The Ask

front_matter

Open slide detail